Dermira buys option for three dermatology programs from Takeda

13 September 2016

US dermatological firm Dermira (Nasdaq: DERM) has entered into an exclusive option and license agreement with Takeda Pharmaceutical (TYO: 4502), Japan’s largest drugmaker, for worldwide rights for up to three early-stage, small-molecule programs as potential topical treatments for dermatologic diseases.

“This transaction supports our commitment to identifying and developing differentiated product candidates that could one day provide benefit to the millions of patients living with dermatologic diseases,” said Luis Peña, chief development officer of Dermira, adding: “We look forward to evaluating these new programs as part of our ongoing effort to identify additional opportunities, including clinical-stage programs, to enhance and broaden our existing product development portfolio.”

Financial terms

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK